Clinical Trials
21 trialsNCT02389309 2026-03-09
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04510051 2026-03-05
CAR T Cells After Lymphodepletion for the Treatment of IL13RĪ±2 Positive Recurrent or Refractory Brain Tumors in Children
City of Hope Medical Center
Phase 1 Recruiting
NCT03152318 2026-03-04
rQNestin
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT02574728 2026-03-02
AflacST1502
Emory University
Phase 2 Active not recruiting
NCT05535166 2026-02-12
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT07390539 2026-02-05
B7-H3.CD28Z.CART in CNS Neoplasms
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07087002 2026-01-27
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Stanford University
Phase 1 Recruiting
NCT05106296 2026-01-09
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Phase 1 Recruiting
NCT04049669 2026-01-08
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Augusta University
Phase 2 Active not recruiting
NCT02066220 2025-12-04
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
UniversitƤtsklinikum Hamburg-Eppendorf
Phase 2/3 Active not recruiting
NCT01878617 2025-11-13
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT03396575 2025-10-29
BRAVO
University of Florida
Phase 1 Terminated
NCT07199413 2025-09-30
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT04023669 2025-02-07
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT06640582 2024-11-05
BAH2472
Essen Biotech
Phase 1/2 Recruiting
NCT02774291 2023-08-04
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
Albert Einstein College of Medicine
Phase EARLY_PHASE1 Terminated
NCT01014767 2019-08-20
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Tufts Medical Center
Phase 3 Terminated
NCT00031590 2019-04-25
Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma
Children's Hospital of Philadelphia
Phase 2 Terminated
NCT00047281 2017-07-11
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00795678 2013-08-02
Chemotherapeutic Agents in Brain/Breast
Case Comprehensive Cancer Center
Completed
NCT00014573 2013-04-08
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed